{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Copd&page=23",
    "query": {
      "condition": "Copd",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 1263,
    "total_pages": 127,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Copd&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Copd&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T20:07:00.027Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00782535",
      "title": "Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "CHF 4226 pMDI",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2008-12",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2019-11-06",
      "last_synced_at": "2026-10-27T20:07:00.027Z",
      "location_count": 5,
      "location_summary": "DeLand, Florida • Madisonville, Kentucky • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Madisonville",
          "state": "Kentucky"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00782535"
    },
    {
      "nct_id": "NCT01558817",
      "title": "Changing the Paradigm of In-Hospital Cardiopulmonary Resuscitation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Oxygen Dependent COPD",
        "Advanced Malignancy"
      ],
      "interventions": [
        {
          "name": "Informed Assent",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Informational Brochure",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2012-02",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2025-05-14",
      "last_synced_at": "2026-10-27T20:07:00.027Z",
      "location_count": 3,
      "location_summary": "Charleston, South Carolina • Burlington, Vermont • Seattle, Washington",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01558817"
    },
    {
      "nct_id": "NCT07554352",
      "title": "Early Detection of COPD Exacerbations Using Home Monitoring Device",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COPD Exacerbation"
      ],
      "interventions": [
        {
          "name": "RespirAI",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "RespirAI US Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-08-05",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-27T20:07:00.027Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07554352"
    },
    {
      "nct_id": "NCT01712516",
      "title": "A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "QVA149",
          "type": "DRUG"
        },
        {
          "name": "QAB149",
          "type": "DRUG"
        },
        {
          "name": "NVA237",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1001,
      "start_date": "2012-12",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2015-07-15",
      "last_synced_at": "2026-10-27T20:07:00.027Z",
      "location_count": 56,
      "location_summary": "Huntsville, Alabama • *See Various Dept.'s*, Arizona • Tempe, Arizona + 46 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "*See Various Dept.'s*",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01712516"
    },
    {
      "nct_id": "NCT05457868",
      "title": "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Salbutamol",
          "type": "DRUG"
        },
        {
          "name": "LAMA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 124117,
      "start_date": "2021-02-01",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-10-27T20:07:00.027Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05457868"
    },
    {
      "nct_id": "NCT01772147",
      "title": "Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Umeclidinium bromide 62.5mcg",
          "type": "DRUG"
        },
        {
          "name": "Umeclidinium bromide 125mcg",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone propionate 250mcg/Salmeterol 50mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 608,
      "start_date": "2013-01",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2017-03-23",
      "last_synced_at": "2026-10-27T20:07:00.027Z",
      "location_count": 17,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 13 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01772147"
    },
    {
      "nct_id": "NCT02713347",
      "title": "Advancing Symptom Alleviation With Palliative Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Failure",
        "Pulmonary Disease, Chronic Obstructive",
        "Emphysema",
        "Pulmonary Fibrosis, Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "ADAPT Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 306,
      "start_date": "2016-09-01",
      "completion_date": "2021-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-10-27T20:07:00.027Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Seattle, Washington",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02713347"
    },
    {
      "nct_id": "NCT00763035",
      "title": "Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Asthma",
        "Chronic Obstructive Pulmonary Disease (COPD)",
        "Angina"
      ],
      "interventions": [
        {
          "name": "Regadenoson",
          "type": "DRUG"
        },
        {
          "name": "Dobutamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 14,
      "start_date": "2009-01",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2018-09-26",
      "last_synced_at": "2026-10-27T20:07:00.027Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00763035"
    },
    {
      "nct_id": "NCT01715298",
      "title": "NVA237 BID Versus Placebo Twelve-week Efficacy Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "NVA237",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 432,
      "start_date": "2012-11",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2015-03-11",
      "last_synced_at": "2026-10-27T20:07:00.027Z",
      "location_count": 59,
      "location_summary": "*See Various Dept.'s*, Arizona • Chandler, Arizona • Fresno, California + 48 more",
      "locations": [
        {
          "city": "*See Various Dept.'s*",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Yorba Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01715298"
    },
    {
      "nct_id": "NCT00821093",
      "title": "Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Indacaterol 150 µg",
          "type": "DRUG"
        },
        {
          "name": "Salmeterol 50 µg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to indacaterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo to salmeterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1123,
      "start_date": "2009-01",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2011-08-18",
      "last_synced_at": "2026-10-27T20:07:00.027Z",
      "location_count": 74,
      "location_summary": "Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00821093"
    }
  ]
}